Sunovion Pharmaceuticals, Inc., Marlborough, MA 01752, USA.
ICON Health Economics, New York, NY 10017, USA.
J Comp Eff Res. 2018 Aug;7(8):737-748. doi: 10.2217/cer-2018-0016. Epub 2018 Apr 26.
To assess the relative efficacy and metabolic effects of lurasidone and brexpiprazole in the acute treatment of schizophrenia. Five lurasidone and three brexpiprazole trials were identified. In the absence of head-to-head trials, a Bayesian network meta-analysis comparing lurasidone and brexpiprazole was performed. Nonstatistically significant differences in efficacy measures were observed between lurasidone and brexpiprazole. Significant differences favoring lurasidone for weight change (-0.69 kg; 95% CrI: -1.22 to -0.15), total cholesterol (-7.60 mg/dl; 95% CrI: -13.94 to -1.22), and low-density lipoprotein (-6.58 mg/dl; 95% CrI: -12.11 to -1.04) were observed, with a trend indicating half the risk of experiencing ≥7% weight gain. This network meta-analysis suggested that lurasidone had similar efficacy and fewer metabolic effects than brexpiprazole in patients with acute schizophrenia.
评估鲁拉西酮和布瑞哌唑在精神分裂症急性期治疗中的相对疗效和代谢效应。 确定了五项鲁拉西酮试验和三项布瑞哌唑试验。 在缺乏头对头试验的情况下，对鲁拉西酮和布瑞哌唑进行了贝叶斯网络荟萃分析。 鲁拉西酮和布瑞哌唑的疗效指标未见统计学差异。 体重变化（-0.69 公斤；95%可信区间：-1.22 至 -0.15）、总胆固醇（-7.60 毫克/分升；95%可信区间：-13.94 至 -1.22）和低密度脂蛋白（-6.58 毫克/分升；95%可信区间：-12.11 至 -1.04）方面有利于鲁拉西酮，且体重增加≥7%的风险降低一半，表明存在趋势。 这项网络荟萃分析表明，在急性精神分裂症患者中，鲁拉西酮的疗效与布瑞哌唑相当，但代谢效应较少。
